Effect of Omega-3 on Blood Inflammation in Overweight and Liver Fat Patients

Not Applicable

• Conditions: Inflammatory liver disease, unspecified; K75.9

• Registration Number: RBR-7x8tbx
• Lead Sponsor: FCA Unicamp

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with excess body weight (body mass index (BMI) greater than or equal to 25.0 kg / m2) between the ages of 19 and 75, of both sexes, diagnosed by the physician of the Hospital Universitário, Universidade Federal de Sergipe, Hepatology Outpatient Clinic with fNon-alcoholic fatty liver disease (NAFLD), as a result of the presence of fat in the liver by ultrasonography, negative serological results for hepatitis B and C, absence of autoimmune diseases, absence of current or previous clinical history of alcohol abuse, absence of other liver diseases caused toxins or metabolites (eg corticosteroids, high doses of estrogen, methotrexate, tetracycline, calcium channel blockers, amiodarone or tamoxifen). The patients should be residents of the Aracaju Metropolitan Region, which is composed by the cities of Aracaju, Nossa Senhora do Socorro, Barra dos Coqueiros and São Cristovão.

Exclusion Criteria

Patients pregnant, nursing, allergic to fish and crustaceans, smokers, carriers of diseases that can lead to change in body weight such as hypo or hyperthyroidism, hypogonadism, hyperandrongenism in women, Cushing's syndrome and other types of secondary obesity, as well chronic kidney disease, cancers and inflammatory bowel disease. Also excluded are individuals taking anti-inflammatory drugs and who in the last three months prior to the study made use of nutritional supplements such as vitamins, minerals, oils and fats or those who are doing some treatment for weight loss and those who have lost more than 10% body weight in the last month.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expect to find decreased protein content of immunoblotted TNF-alpha and IL-6 in mononuclear cells and neutrophils in the omega-3 supplemented group compared to the placebo group.

Secondary Outcome Measures

Name	Time	Method
o Secondary Outcomes Expected